F2G Ltd, A Uk- And Austria-Based Biotech Company Developing Novel Therapies For Life-Threatening Systemic Fungal Infections, Announced That The Us Food And Drug Administration (Fda) Has Granted Breakthrough Therapy Designation To Its Lead First-In-Class Candidate, Olorofim (Formerly F901318) For The Indication Of â
